Vimarsana
Biggest News Aggregation in the World

Page 4 - Deric Dube News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Deric Dube. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Deric Dube Today - Breaking & Trending Today

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2023 Earnings Call Transcript - Vimarsana News

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2023 Earnings Call Transcript

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2023 Earnings Call Transcript August 4, 2023 Operator: Good day, and welcome to the Travere Therapeutics Second Quarter 2023 Financial Results and Corporate Update Conference Call. Today’s conference call is being recorded. At this time, I would like to turn the conference call over to the Vice President of Investor […]

Source: yahoo.com
San Diego's Travere Therapeutics to sell a piece of its liver disorder drug portfolio for $445M - Vimarsana News

San Diego's Travere Therapeutics to sell a piece of its liver disorder drug portfolio for $445M

Mirum Pharmaceuticals gets two FDA-approved drugs targeting people with rare liver and kidney disorders

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2023 Earnings Call Transcript - Vimarsana News

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2023 Earnings Call Transcript

Operator: Good day, and welcome to the Travere Therapeutics First Quarter 2023 Financial Results and Corporate Update Conference Call. Today's conference is being recorded.

Travere set back by study failure of kidney disease drug - Vimarsana News

Travere set back by study failure of kidney disease drug

BioPharma

Travere Therapeutics Drug for Rare Kidney Disease Falls Short in Pivotal Test - Vimarsana News

Travere Therapeutics Drug for Rare Kidney Disease Falls Short in Pivotal Test

Sparsentan failed to meet the main goal of a Phase 3 test in focal segmental glomerulosclerosis (FSGS). Nevertheless, Travere Therapeutics says the totality of data points to patient improvement in the rare kidney disorder and the biotech will talk with regulators about a potential path forward.